Extended trial tests Long-Term safety of new hormone disorder drug
Disease control
Ongoing
This study follows patients who completed a previous 12-week trial to check the long-term safety of MBX 2109, a weekly injection for hypoparathyroidism. It involves 60 adults with this hormone disorder who will continue treatment to monitor side effects and see if the drug helps …
Phase: PHASE2 • Sponsor: MBX Biosciences • Aim: Disease control
Last updated Mar 02, 2026 15:22 UTC